Indeed, the authors stated: 'There was a notable lack of detail regarding how adverse events were measured and classified. Furthermore, the short-term follow-up in many trials, combined with potential under-reporting of adverse events, raised concerns about the data completeness.'

Hi Brooke! Thank you for the initiative! Can I be add for the early career and phd searching postdoc? Thanks ✨